English
Back
Open Account

港CXO板塊集體走強,行情見底了嗎?

2月15日,港CXO板塊集體走強,藥明康德漲超11%,泰格醫藥漲超5%,康龍化成漲3.8%。近日,NMPA應急批准Paxlovid,用於治療成人伴有重症風險的輕至中度COVID-19患者。多家機構表示CXO板塊估值底部逐步顯現,外部利好催化不斷,看好CXO行情。
2月15日,港CXO板塊集體走強,藥明康德漲超11%,泰格醫藥漲超5%,康龍化成漲3.8%。近日,NMPA應急批准Paxlovid,用於治療成人伴有重症風險的輕至中度COVID-19患者。多家機構表示CXO板塊估值底部逐步顯現,外部利好催化不斷,看好CXO行情。
Views
148K
Posts
20
Join topic
Latest
Hot
    $WUXI BIO (02269.HK)$
    Domestic CXO is competitive in the international arena. What is the core competitiveness? Engineer bonus! What are the main costs of CXO? Labor cost! Why, because CXO is actually a service industry! Sell services, sell experimental data. Only part of the front-end CDMO will sell some semi-finished products for processing.
    At present, the average domestic labor cost is 1 CXO 3, why international pharmaceutical companies are willing to give a list to China's CRO, because it is cheap. CXO is actually an alternative service manufacturing industry that makes data, compounds and proteins.
    Why do foreign big pharmaceutical companies not go to Vietnam, Cambodia to do substitute processing, because there is no talent, these are undergraduate, graduate students account for a large proportion of the industry, that is, China is now rampant and cheap.
    Therefore, as long as the engineer dividend, the domestic CXO still has a competitive advantage, look at the foreign CRO revenue, there is still a lot of room for improvement.
    $WUXI APPTEC (02359.HK)$ $TIGERMED (03347.HK)$ $INNOVENT BIO (01801.HK)$
    2
    2
Unlock Pro Investors’ Money-Making Secrets
Join Futubull Community! Now Connect Directly with Top Investors & Public Company Executives
Unlock it Now
Related Stocks
  • 03347
    TIGERMED
    32.620
    +1.12%
  • 06127
    JOINN
    16.420
    +2.18%
  • 06821
    ASYMCHEM
    92.750
    +2.20%
  • 03759
    PHARMARON
    15.520
    +3.95%
  • 02359
    WUXI APPTEC
    126.700
    +2.67%